Hepatorenal syndrome secondary prevention

	Hepatorenal syndrome Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Hepatorenal syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Hepatorenal syndrome secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Hepatorenal syndrome secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Hepatorenal syndrome secondary prevention
CDC on Hepatorenal syndrome secondary prevention
Hepatorenal syndrome secondary prevention in the news
Blogs on Hepatorenal syndrome secondary prevention
Directions to Hospitals Treating Hepatorenal syndrome
Risk calculators and risk factors for Hepatorenal syndrome secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

A randomized controlled trial found that intravenous albumin on the day of admission and on hospital day 3 can reduce renal impairment.^[1]

↑ Sort P, Navasa M, Arroyo V; et al. (1999). "Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis". N. Engl. J. Med. 341 (6): 403–9. PMID 10432325.